

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Release and Termination of Security Interest Solely in the Collateral Listed in Schedule A (See Document for Details)

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
DEUTSCHE BANK TRUST COMPANY AMERICAS (AS INDENTURE TRUSTEE)		09/30/2005	CORPORATION: NEW YORK

**RECEIVING PARTY DATA**

<b>Name:</b>	ARTERY, LLC
<b>Street Address:</b>	222 Delaware Avenue
<b>Internal Address:</b>	10th Floor
<b>City:</b>	Wilmington
<b>State/Country:</b>	DELAWARE
<b>Postal Code:</b>	19801
<b>Entity Type:</b>	LIMITED LIABILITY COMPANY: DELAWARE

<b>Name:</b>	GUILFORD PHARMACEUTICALS, INC.
<b>Street Address:</b>	6611 Tributary Street
<b>City:</b>	Baltimore
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	21224
<b>Entity Type:</b>	LIMITED LIABILITY COMPANY: DELAWARE

**PROPERTY NUMBERS Total: 4**

Property Type	Number	Word Mark
Registration Number:	1650461	GLIADEL
Registration Number:	2027788	AGGRASTAT
Registration Number:	2713360	PROLONG
Registration Number:	2717403	CARE

**CORRESPONDENCE DATA**

**900033303**

**TRADEMARK  
 REEL: 003170 FRAME: 0081**

**CH \$115.00 1650461**

Fax Number: (703)816-4100  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 703-816-4057  
Email: wfg@nixonvan.com  
Correspondent Name: Willem F. Gadiano  
Address Line 1: NIXON & VANDERHYE P.C.  
Address Line 2: 901 North Glebe Road, 11th Floor  
Address Line 4: Arlington, VIRGINIA 22309-1808

ATTORNEY DOCKET NUMBER:	4379-4
NAME OF SUBMITTER:	Willem F. Gadiano
Signature:	/Willem Gadiano/
Date:	10/04/2005

**Total Attachments: 7**

source=4379-4 release#page1.tif  
source=4379-4 release#page2.tif  
source=4379-4 release#page3.tif  
source=4379-4 release#page4.tif  
source=4379-4 release#page5.tif  
source=4379-4 release#page6.tif  
source=4379-4 release#page7.tif

**RELEASE AND TERMINATION OF SECURITY INTEREST**

**THIS RELEASE** is made effective September 30, 2005, by **Royalty Securitization Trust I**, a statutory trust organized under the laws of Delaware ("RST"), **Deutsche Bank Trust Company Americas**, a New York banking corporation, not in its individual capacity but solely as Indenture Trustee ("DBTC"), **Paul Royalty Fund Holdings II**, a California general partnership, ("PRII" and, together with RST and DBTC, "Secured Parties" and each individually a "Secured Party") for the benefit of **Artery, LLC**, a Delaware limited liability company ("Artery") and **Guilford Pharmaceuticals Inc.**, a Delaware corporation ("Guilford"), their successors and assigns.

**WHEREAS**, PRII, Paul Royalty Fund, L.P., a Delaware limited partnership ("PRF"), Artery, Guilford and GPI Investments, LLC, a Delaware limited liability company formerly known as GPI Holdings, Inc., ("GPI" and, together with Guilford and Artery, "Released Parties" and each individually a "Released Party") are parties to that certain Revenue Interest Assignment Agreement dated as of October 28, 2003 ("RIAA").

**WHEREAS**, PRF has assigned its interest under the RIAA to Royalty Financial Company LLC, which in turn assigned its interest to RST, which in turn pledged its interest to DBTC;

**WHEREAS**, The Secured Parties each hold a Security Interest in and to certain intellectual properties owned or licensed by a Released Party, including, without limitation, the intellectual properties listed on Schedule A, attached hereto (collectively referred to herein as "Intellectual Property Collateral"), arising out of the RIAA and related documents; and

**WHEREAS**, The Secured Parties each wish to release its Security Interest in and to said Intellectual Property Collateral;

**NOW, THEREFORE**, in consideration of the foregoing premises and of other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree, as follows:

1. As of the date of this Release, each Secured Party does hereby terminate and release any lien, claim, encumbrance or interest in and to the Intellectual Property Collateral, which at least includes certain utility patents and trademarks listed in the United States Patent and Trademark Office records at the following Reel/Frame Nos.:

Reel	Frame	Date Recorded	Conveying Party	Receiving Party	Doc Date	Type
014108	0569	11-07-03	Guilford	PRII	10-28-03	Patent
014108	0601	11-07-03	Artery	PRII	10-28-03	Patent
002744	0099	11-07-03	Guilford	PRII	10-28-03	Trademark
002744	0132	11-07-03	Artery	PRII	10-28-03	Trademark
014709	0075	06-04-04	Guilford	PRII	10-28-03	Patent
014692	0729	06-04-04	Artery	PRII	10-28-03	Patent
015478	0090	12-20-04	Guilford	PRII	10-28-03	Patent
015478	0785	12-20-04	Artery	PRII	10-28-03	Patent
015603	0752	01-19-05	RFC	RST	11-19-04	Patent
003011	0356	01-11-05	RFC	RST	11-19-04	Trademark
015603	0896	01-12-05	RST	DBTC	11-19-04	Patent
003012	0040	01-12-05	RST	DBTC	11-19-04	Trademark


2. Nothing in this Release shall adversely affect, in any manner whatsoever, the security interests held by RST and DBTC in and to other intellectual properties that are not owned or licensed by a Released Party or not specifically included on Schedule A, which security interests remain in full force and effect.
3. Each Secured Party undertakes and agrees to do all acts and things and/or execute any further documents as Released Parties may reasonably request to carry into effect or to give legal effect to the provisions of this Release.
4. This Release may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute a single agreement.
5. This Release may not be changed except in a writing signed by the party against whose interest such change shall operate. This Release shall be governed by and construed under the laws of the State of New York applicable to contracts made and to be performed entirely within such State, without regard to principles of conflicts of law.

*[Remainder of Page Intentionally Left Blank]*


IN WITNESS WHEREOF, the parties have caused this Release to be duly executed as of the date first written above.

SECURED PARTIES:                   **ROYALTY SECURITIZATION TRUST I**

By: Deutsche Bank Trust Company Delaware, not in its individual capacity, but solely as Owner Trustee

By:   
Name: \_\_\_\_\_  
Title: VICE PRESIDENT

**DEUTSCHE BANK TRUST COMPANY AMERICAS, AS  
INDENTURE TRUSTEE**


By:   
Name: ADAMS HODI  
Title: VICE PRESIDENT

**PAUL ROYALTY FUND HOLDINGS II**

By: Paul Royalty Fund II, L.P.,  
its Managing Partner

By: Paul Capital Royalty Management, LLC,  
its General Partner


By: Paul Capital Advisors, L.L.C.,  
its Manager

By:   
Name: Lionel Leventhal  
Title: Manager


*[Signature Page To Release and Termination of Security Interest]*

RELEASED PARTIES:


**ARTERY, LLC**

By:   
Name: Asher M. Rubin  
Title: Vice President

**GUILFORD PHARMACEUTICALS INC.**

By:   
Name: Dean J. Mitchell  
Title: President

**GPI INVESTMENTS, LLC**

By:   
Name: Asher M. Rubin  
Title: Vice President

*[Signature Page To Release and Termination of Security Interest]*

## SCHEDULE A

### United States Patents

Patent No.	Appl No.	Title
4757128	06/892,809	Synthesis And Application Of High Molecular Weight Polyanhydride
4789724	06/920,724	Preparation Of Anhydride Copolymers
5179189	07/756,483	Fatty Acid Terminated Polyanhydrides
5292756	07/860,747	Sulfonamide Fibrinogen Receptor Antagonists
5658929	08/505,417	Sulfonamide Fibrinogen Receptor Antagonists
5733919	08/735,878	Compositions For Inhibiting Platelet Aggregation
5814643	08/861,545	Sulfonamide Fibrinogen Receptor Antagonists
5965581	09/079,776	Compositions For Inhibiting Platelet Aggregation
5972967	08/965,922	Compositions For Inhibiting Platelet Aggregation
5978698	08/943,872	Angioplasty Procedure Using Nonionic Contrast Media
5880136	09/130,334	Sulfonamide Fibrinogen Receptor Antagonists
6040317	09/221,044	Sulfonamide Fibrinogen Receptor Antagonists
6136794	09/240,429	Platelet Aggregation Inhibition Using Low Molecular Weight Heparin In Combination With A GP IIb/IIIa Antagonist
6770660	10/427,436	Method For Inhibiting Platelet Aggregation

## SCHEDULE A

### Foreign Patents

<b>Country</b>	<b>Patent No. (or Publication No.)</b>
Austria	0260415
Austria	26603A1
Belgium	0260415
Belgium	26603A1
Canada	1274339
Canada	1278141
Europe	0260415
Europe	266603A1
France	26603A1
France	0260415
Germany	DE3751964D
Germany	26603A1
Great Britain	0260415
Great Britain	26603A1
Greece	26603A1
Greece	0260415
Italy	0260415
Italy	26603A1
Japan	2700646
Japan	2626717
Korea	9606410
Liechtenstein	0260415
Liechtenstein	26603A1
Luxembourg	0260415
Luxembourg	26603A1
Netherlands	0260415
Netherlands	26603A1
Spain	26603A1
Spain	2006417
Sweden	0260415
Switzerland	0260415
Switzerland	26603A1
Taiwan	46779



**SCHEDULE A**

**U.S. Trademarks**

<b>Mark</b>	<b>Reg. No.</b>	<b>Appl No.</b>
GLIADEL	1650461	74/006093
AGGRASTAT	2027788	74/660332
PROLONG	2713360	76/429455
CARE	2717403	76/429459

**Foreign Trademarks**

<b>TRADEMARK: GLIADEL</b>		
<b>COUNTRY</b>	<b>REG. NO.</b>	<b>REG. DATE</b>
Argentina	1848791	10/26/01
Australia	673953	01/31/97
Austria	161295	12/05/95
Benelux	582765	09/02/96
Brazil	N/A (App. no. 820581488)	N/A (Filed: 02/17/98)
Canada	475,108	04/23/97
Chile	513147	05/26/98
China (Prc)	1032540	06/21/97
Colombia	212145	08/25/99
Denmark	7341 1995	10/24/95
Ecuador	5532-98	10/06/98
Finland	201128	07/15/96
France	95591029	03/15/96
Germany	39541840	05/09/96
Greece	135860	08/17/99
Ireland	168898	03/24/97
Israel	101178	07/02/97
Italy	750817	05/22/98
Japan	4046979	08/22/97
Japan	4131704	04/03/98
Korea	361871	05/12/97
Mexico	575836	03/30/98
New Zealand	254244	10/07/097
Norway	178037	11/14/96
Peru	044624	02/18/98
Portugal	312918	08/08/96
Singapore	T95/09679Z	11/11/99
South Africa	95/13155	04/12/99
Spain	1994128	01/20/97
Sweden	311551	04/12/96
Switzerland	432358	12/09/96
Taiwan	737210	12/01/96
Turkey	163927	07/23/98
United Kingdom	2039450	06/26/98
Uruguay	298274	05/27/98
Venezuela	P208835	10/30/08